Edition:
United States

Catalyst Pharmaceuticals Inc (CPRX.OQ)

CPRX.OQ on NASDAQ Stock Exchange Capital Market

3.43USD
16 Feb 2018
Change (% chg)

$-0.10 (-2.83%)
Prev Close
$3.53
Open
$3.50
Day's High
$3.58
Day's Low
$3.42
Volume
72,578
Avg. Vol
227,555
52-wk High
$4.51
52-wk Low
$1.08

Chart for

About

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's... (more)

Overall

Beta: 1.33
Market Cap(Mil.): $295.14
Shares Outstanding(Mil.): 86.05
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Catalyst Pharmaceuticals Announces Plans To Resubmit New Drug Application For Firdapse

* CATALYST PHARMACEUTICALS ANNOUNCES PLANS TO RESUBMIT NEW DRUG APPLICATION FOR FIRDAPSE®

Feb 12 2018

BRIEF-Great Point Partners Reports 5.14 Pct Passive Stake In Catalyst Pharma

* GREAT POINT PARTNERS LLC REPORTS A 5.14 PERCENT PASSIVE STAKE IN CATALYST PHARMACEUTICALS INC AS OF NOV 28 - SEC FILING Source text for Eikon: (http://bit.ly/2jaVqTo) Further company coverage:

Dec 08 2017

BRIEF-Catalyst Pharmaceuticals Inc Prices Previously Announced Public Offering Of Common Stock

* CATALYST PHARMACEUTICALS, INC. PRICES PREVIOUSLY ANNOUNCED PUBLIC OFFERING OF COMMON STOCK

Nov 28 2017

BRIEF-Catalyst Pharma Announces Proposed Public Offering Of Common Stock

* CATALYST PHARMACEUTICALS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Nov 27 2017

BRIEF-Catalyst Pharma Posts Positive Top-Line Results From Second Phase 3 Clinical Trial Of Firdapse

* CATALYST PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM SECOND PHASE 3 CLINICAL TRIAL OF FIRDAPSE® IN PATIENTS WITH LAMBERT-EATON MYASTHENIC SYNDROME

Nov 27 2017

BRIEF-Catalyst Pharmaceuticals ‍announces phase 2 study of Firdapse

* Announces phase 2 study of Firdapse in ambulatory patients with spinal muscular atrophy​

Nov 21 2017

BRIEF-Catalyst Pharmaceuticals posts Q3 loss per share $0.05

* Catalyst Pharmaceuticals announces third quarter 2017 financial results and provides corporate update

Nov 08 2017

BRIEF-Catalyst Pharmaceuticals completes enrollment in second Phase 3 trial of Firdapse®

* Catalyst Pharmaceuticals completes enrollment in second Phase 3 trial of Firdapse® in patients with Lambert-Eaton Myasthenic Syndrome

Oct 31 2017

BRIEF-Catalyst Pharmaceuticals provides update on the status of its Firdapse development activities

* Catalyst Pharmaceuticals provides update on the status of its Firdapse development activities

Aug 30 2017

Earnings vs. Estimates